Anthrax is linked to some bioterrorist attacks. In 2001, five people died when they inhaled anthrax spores sent in the mail. Many other people developed symptoms like skin infections. “To support the nation’s preparedness against a possible anthrax attack, the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) purchased Anthrasil under Project BioShield in 2011 as an experimental drug for the U.S. Strategic National Stockpile,” the FDA revealed. The producer of the new drug, Emergent BioSolutions, is a global specialty biopharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats.